Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline plc : Director/PDMR Shareholding

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/03/2012 | 08:11pm CEST

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the interests of a Person Discharging Managerial Responsibility in the Ordinary Shares of GlaxoSmithKline plc ("Ordinary Shares") on 2 May 2012:

Mr S M Bicknell

Transfer of 250 Ordinary Shares into an ISA at £14.3225 per share.



The Company and the above mentioned person was advised of this transaction on 3 May 2012.

This notification relates to a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

3 May 2012


This information is provided by RNS
The company news service from the London Stock Exchange
ENDRDSQXLFBLEFXBBD
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
09/21 GLAXOSMITHKLINE : Studies from GlaxoSmithKline plc Provide New Data on Drug Deve..
09/21 GLAXOSMITHKLINE : Findings from GlaxoSmithKline plc in the Area of Chemical Biol..
09/21 AGENUS : GSK's Shingrix containing Agenus' QS-21 Stimulon® adjuvant receives Una..
09/21 GLAXOSMITHKLINE : UK Trade Minister visits GSK Pakistan
09/21 GLAXOSMITHKLINE : 11% Potential Upside Indicated by Deutsche Bank
09/20 GLAXOSMITHKLINE : GSK's new triple lung drug beats other modern inhalers in stud..
09/20DJGLAXOSMITHKLINE : Announces Positive Results for Triple-Therapy Inhaler
09/20 GLAXOSMITHKLINE : Positive IMPACT results for Trelegy in COPD
09/20 GLAXOSMITHKLINE : GSK and Innoviva Report Positive Headline Results from IMPACT ..
09/19 GLAXOSMITHKLINE : FDA OKs Glaxo's inhaler, first one to combine 3 medicines
More news
News from SeekingAlpha
09/25 Hurricane Lessons
09/25 Alnylam And Sanofi Achieve An RNAi First
09/24 J&J : Thoughts On Sirukumab And Other Problems
09/21 FDA's Woodcock says clinical trials system "broken"
09/20 'Safer' Dividend Follower Favorites And Rogues Led By Capitala Finance
Financials ( GBP)
Sales 2017 30 232 M
EBIT 2017 8 500 M
Net income 2017 4 195 M
Debt 2017 14 079 M
Yield 2017 5,43%
P/E ratio 2017 19,13
P/E ratio 2018 15,41
EV / Sales 2017 2,86x
EV / Sales 2018 2,78x
Capitalization 72 499 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 17,2  GBP
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-5.63%97 830
JOHNSON & JOHNSON14.36%352 651
NOVARTIS12.62%224 990
ROCHE HOLDING LTD.6.62%220 358
PFIZER10.75%214 146
MERCK AND COMPANY11.43%177 633